Therapeutic decisions in a cohort of patients with idiopathic pulmonary fibrosis: a multicenter, prospective survey from Poland.

"Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Honoraria for lectures; payment to Author Support for attending meetings and/or travel – fee, travel, and accommodation. K.G. and M.M.-W. report honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim, outside the submitted work; M.B. reports honoraria for lectures by Chiesi Pharmaceuticals GmbH, Roche and Boehringer Ingelheim. A.Bi. reports honoraria for lectures, payment for expert testimony and support for attending meetings and travel by Chiesi Poland; A.Ba. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim; H.J.-L. reports honoraria for lectures, receipt of equipment, materials, drugs, medical writing, gifts and other services and support for attending meetings and travel by Roche and Boehringer Ingelheim; E.J. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Roche and Boehringer Ingelheim, outside the submitted work; A.K. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Boehringer Ingelheim, outside the submitted work; K.L. reports honoraria for lectures and supports for attending meetings and travels by Roche and Boehringer Ingelheim and declares participation on an advisory board by Boehringer Ingelheim and patients’ advocacy advisory board by Roche, she reports the role as a leadership or fiduciary role in EU-IPFF Scientific Committee and in Polish IPF Patients’ Support Society; S.M. and W.J.P. report consulting fees, honoraria for lectures, support for attending meetings and travel by Boehringer Ingelheim and participation in Boehringer Ingelheim’s Advisory Boards, outside the submitted work; M.M.-B. has nothing to disclose; A.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim; K.S. has nothing to disclose. M.S. reports honoraria for lectures by Roche and Boehringer Ingelheim, support for attending meetings and travel by Roche and Boehringer Ingelheim and participation in Advisory Boards by Boehringer Ingelheim and reports the role as a member of the Audit Committee in Polish IPF Patients’ Support Society; M.T-S. and W.T. have nothing to disclose; B.Ż. reports support for attending meetings and travel by Roche, Boehringer Ingelheim, Chiesi Pharmaceuticals GmbH; R.K. reports support for attending meetings and travel by Boehringer Ingelheim and participation in Advisory Boards for MSD, outside the submitted work."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The publication of this study was funded by Roche Polska without any involvement in this study design, data collection, analysis and interpretation or decision to submit the article."